The new Medicare drug-price rules in the Inflation Reduction Act threaten the economics of long-term-care pharmacies, the specialized suppliers that keep nursing homes running; if their margins collapse, medication access for millions of elderly residents could be disrupted, pushing more people into emergency rooms and hospitals and driving up costs across the system unless Congress or CMS steps in with a temporary fix.

America’s Nursing-Home Pharmacy System Is About to Break

Washington celebrated lower drug prices and a $2,000 out-of-pocket cap, and those wins matter to patients. But tucked behind the headlines is a fragile corner of health care few follow closely: the pharmacies that supply nursing homes. Their stability determines whether residents get the daily medications they depend on.

Long-term-care pharmacies are not retail shops with walk-in customers and diversified product lines. They package medicines into unit doses, handle emergency deliveries, stock medication carts at nursing stations, and provide around-the-clock pharmacist support for patients with multiple chronic conditions. Federal rules expect nursing homes to provide those services, and LTC pharmacies are built to meet that expectation.

The business model for these pharmacies depends on reimbursement that covers the labor-intensive services they deliver. When drug reimbursement drops, the slim margins that fund those services evaporate fast. Retail chains can absorb margin pressure; LTC pharmacies typically cannot.

Starting in 2026, Medicare will apply negotiated maximum fair prices from the IRA to selected drugs. That change will lower prices for beneficiaries but also remove the margins LTC pharmacies use to fund operations. An economic analysis based on thousands of LTC pharmacies projects about a 35 percent decline in operating margins during the first two years of implementation, which is a severe shock for a low-margin sector.

Pharmacy operators are already raising alarms. A national survey by the Senior Care Pharmacy Coalition found large shares expecting closures, layoffs, and reduced services. Those results reflect real, on-the-ground concerns about whether pharmacies can keep serving nursing homes while absorbing reduced reimbursement.

If closures occur at scale, nursing homes will face trouble meeting federal requirements for medication management. Delays and service disruptions would emerge quickly, and residents with complicated medication regimens would suffer first. That kind of operational breakdown is not simply inconvenient; it can cause harm and heighten clinical risk.

LTC pharmacies play a preventive role. They reduce medication errors, keep dosing schedules precise, and help prevent frail patients from spiraling into acute care. When that safety net frays, emergency-room visits and hospital admissions rise, which hits patients and drives up Medicare spending.

Modeling from pharmacy stakeholders suggests modest increases in hospital and ER use could add billions to Medicare costs over a decade. By contrast, stabilizing LTC pharmacies with a temporary payment adjustment would cost a fraction of those downstream increases. That arithmetic undercuts the idea that lower drug prices alone produce net savings without additional adjustments to support essential providers.

Two practical routes could shore up the sector. One is legislative: the Preserving Patient Access to Long-Term Care Pharmacies Act, introduced as H.R. 5031, would create a temporary supply fee for LTC pharmacies dispensing drugs affected by IRA negotiations. That approach aims to replace lost margin while the new pricing regime beds in.

The other path lies with the Department of Health and Human Services. CMS can run demonstration projects under existing authority to stabilize premiums and targeted parts of the Part D market. A short-term demonstration or adjustment aimed at LTC pharmacies could buy time and prevent abrupt cutoffs in service when negotiated prices take effect.

Either option would blunt disruption in 2026, but what matters most is a timely decision. LTC pharmacies and the nursing homes that depend on them need clarity before prices change, not months afterward. The nearer those deadlines get, the harder it will be to avert operational damage.

Health policy often lags behind obvious fixes, and slow fixes here would be costly in human terms. Nursing homes need reliable partners to manage complex medication needs, and residents cannot tolerate interruptions in access to essential drugs. Lawmakers and regulators can choose to prevent a preventable failure, but the window for action is closing.